Daxor Corporation Common Stock vs. ResMed Inc.
ResMed Inc. (RMD) comes out ahead, leading on 7 of 9 compared factors.
Size & Scale
| DXR | RMD | |
|---|---|---|
| Market Cap | $65.10 million | $32.93 billion |
| Revenue (TTM) | $1.45 million | $5.65 billion |
| Net Income (TTM) | $-7,185,639 | $1.52 billion |
RMD leads on 3 of 3 size & scale factors.
Valuation
| DXR | RMD | |
|---|---|---|
| P/E Ratio | — | 21.90 |
| Price / Book | 1.80 | 5.00 |
| Price / Sales | 45.01 | 5.82 |
DXR and RMD split the valuation factors evenly.
Profitability
| DXR | RMD | |
|---|---|---|
| Net Margin | -496.81% | 26.94% |
| Return on Equity | -19.84% | 23.13% |
RMD leads on 2 of 2 profitability factors.
Dividend
| DXR | RMD | |
|---|---|---|
| Dividend Yield | 0.27% | 1.16% |
| Payout Ratio | — | 25.31 |
RMD leads on 1 of 1 dividend factors.
Risk & Sentiment
| DXR | RMD | |
|---|---|---|
| Short Interest | 0.00% | 4.04% |
DXR leads on 1 of 1 risk & sentiment factors.
Dig deeper: DXR overview, DXR financials, RMD overview, RMD financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.